Learn about keratoconus a progressive eye disease affecting young adults Find out its signs causes and treatment options ...

CXL is a technique that uses ultraviolent A (UV-A) light and riboflavin to increase the biomechanical rigidity of the cornea and arrest progression of ectasia in patients with keratoconus.

The accompanying cover story summarizes some pioneering activities in collagen cross-linking for keratoconus.In this commentary, I am going to take a look into the future of CXL and share some of ...

CXL of the cornea using UVA and riboflavin has been found to be effective in halting the progression of keratoconus. [24] There also seems to be a negative association between diabetes mellitus ...

CXL performed after Intacs treatment yielded an additional 1.2 Snellen lines (p < 0.05) of uncorrected visual acuity and 0.36 Snellen lines (p < 0.05) of BCVA.

SHERBORN, Mass.--(BUSINESS WIRE)--CXL Ophthalmics, Inc., a clinical-stage company developing a minimally-invasive treatment for keratoconus, today published results of the EpiSmart cross-linking ...

SHERBORN, Mass.--(BUSINESS WIRE)--CXL Ophthalmics, Inc., a clinical-stage company developing a minimally-invasive treatment for keratoconus, today announced it has raised a $32 million Series A ...

The idea is that EpiSmart can treat keratoconus without disturbing the epithelium tissue, which Epion hopes will allow “for a rapid return to normal activities,” it said in a July 6 press release.

The ACOS CXL trial, which is currently on-going at Ophthalmic Partners, will be accepting patients through December. If you would like to learn more about the trial, please call 215-720-1879 and ...

Pre-2000, the clinical management of keratoconus centred on rigid contact lens fitting when spectacle corrected acuity was no longer adequate, and transplantation where contact lens wear failed ...